Fig. 6: GLUD2 mutation damages mitochondrial function in MPTP-treated mice and MPP+-treated U251 cells.
From: Functional validation of a human GLUD2 variant in a murine model of Parkinson’s disease
a Effect of GLUD2 or its mutant on the mitochondrial membrane potential using JC-1 fluorescent probes in control or MPP+-treated cells (scale bars, upper, 30 µm; lower, 5 µm). b Mito-SOX was used to stain live cells expressing GLUD2 or its mutant in control or MPP+-treated cells (scale bars, 10 µm). c, d Effects of GLUD2 or its mutant on Bax and Bcl-2 expression in the SN of MPTP-treated mice or in MPP+-treated U251 cells were determined by western blotting. n = 6 in (c) and n = 3 in (d). e Immunofluorescent staining of EGFP and Bcl-2 upon expression of GLUD2 or its mutant in control or MPP+-treated U251 cells (scale bars, 10 µm). Results are expressed as the mean ± SEM. **p < 0.01 vs. AAV-GFP group or untreated U251 cells. ##p < 0.01, #p < 0.05 vs. MPTP + AAV-GFP or MPP+ group. &&p < 0.01, &p < 0.05 vs MPTP + AAV-GLUD2 group. Statistical significance was determined by one-way ANOVAs and Tukey tests for post-hoc comparisons.
